Q&A: What does COVID-19 antiviral treatment look like in 2023?

Co-chair of the COVID-19 clinical evidence taskforce discusses emerging treatments and the taskforce’s uncertain future
0
16 February 2023
Save
Please login to bookmark Close

This content has been independently produced by ADG, made possible through sponsorship from Gilead.

In this Q&A, infectious disease physician Professor Josh Davis speaks to ADG about COVID-19 antivirals, both old and new, long COVID challenges, and the reasons molnupiravir (Lagevrio) was downgraded to a last-resort treatment by the National Clinical Evidence Taskforce.

ADG: Do you think the current line-up of COVID-19 antivirals is still fit for purpose or are newer drugs needed to tackle emerging strains?

JD: We need new drugs. But the good news is that there’s a lot in the pipeline. There are 20 or 30 antivirals in phase 2 or 3 clinical trials, and there’s also a number of monoclonal antibodies in clinical trials. None of the current monoclonal antibodies work anymore on the new variants.

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .